Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GTB-3650 |
| Synonyms | |
| Therapy Description |
GTB-3650 is a trispecific Natural Killer (NK) cell engager (TriKE) containing an antibody that targets CD16 on NK cells, a single chain variable fragment targeting CD33 on tumor cells, and a IL15 moiety, which may induce an anti-tumor immune response against tumor cells expressing CD33 (PMID: 32661096). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GTB-3650 | GTB3650|GTB 3650 | CD33 Antibody 17 | GTB-3650 is a trispecific Natural Killer (NK) cell engager (TriKE) containing an antibody that targets CD16 on NK cells, a single chain variable fragment targeting CD33 on tumor cells, and a IL15 moiety, which may induce an anti-tumor immune response against tumor cells expressing CD33 (PMID: 32661096). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06594445 | Phase I | GTB-3650 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | Recruiting | USA | 0 |